ZILVER VENA VENOUS SELF EXPANDING STENT
Report
- Report Number
- 3001845648-2022-00804
- Event Type
- Injury
- Date Received
- November 25, 2022
- Date of Event
- October 26, 2022
- Report Date
- January 17, 2023
- Manufacturer
- COOK IRELAND LTD
- Product Code
- QAN
- Adverse Event
- Yes
- Report Source
- Manufacturer report
- Reporter Occupation
- OTHER
- Health Professional
- N
Narratives
INVESTIGATION IS STILL PENDING, A FOLLOW UP MDR WILL BE SUBMITTED TO INCLUDE THE INVESTIGATION CONCLUSIONS. PMA/510(K) #: P200023. COMMON NAME - QAN.
COMMON NAME: (B)(6). PMA/510(K) #: P200023. DEVICE EVALUATION: THE DEVICE EVALUATION COULD NOT BE COMPLETED AS THE DEVICE OR PHOTOGRAPHIC EVIDENCE OF THE DEVICE WAS NOT RETURNED FOR EVALUATION. WITH THE INFORMATION PROVIDED, A DOCUMENT-BASED INVESTIGATION WAS CONDUCTED. THIS FILE IS RELATED TO PR (B)(4). LAB EVALUATION ¿ N/A. DOCUMENT REVIEW: PRIOR TO DISTRIBUTION ALL ZILVER VENA DEVICES ARE SUBJECTED TO A VISUAL INSPECTION AND FUNCTIONAL INSPECTION TO ENSURE DEVICE INTEGRITY. IT SHOULD BE NOTED THAT THE INSTRUCTIONS FOR USE (IFU0047) LISTS RESTENOSIS OR THROMBOSIS OF THE STENTED VEIN AS A POTENTIAL ADVERSE EVENT. THERE IS NO EVIDENCE TO SUGGEST THE USER DID NOT FOLLOW THE IFU. THERE IS NO EVIDENCE TO SUGGEST THAT THE CUSTOMER DID NOT FOLLOW THE LABEL. IMAGE REVIEW: AN IMAGE WAS NOT RETURNED FOR EVALUATION. ROOT CAUSE REVIEW: A DEFINITIVE ROOT CAUSE COULD NOT BE DETERMINED HOWEVER A POSSIBLE ROOT CAUSE CAN BE ATTRIBUTED TO THE PROCEDURE. ACCORDING TO THE LITERATURE PAPER, THE EVENT WAS ¿NOT RELATED TO ZILVER VENA, IT SHOULD ALSO BE NOTED THAT THE IFU LISTS RESTENOSIS OR THROMBOSIS (OCCLUSION) OF THE STENTED VEIN AS A POTENTIAL ADVERSE EVENT. SUMMARY: THE COMPLAINT IS CONFIRMED BASED ON CUSTOMER TESTIMONY. THE COMPLAINT WAS RAISED FROM THE CLINICAL STUDY ¿EVALUATION OF THE ZILVER VENA VENOUS STENT IN SPAIN ¿ DR. (B)(6) (PHYSICIAN ¿ DRIVEN STUDY ¿ AMBISPECTIVE REVIEW OF PATIENTS UNDERGOING PROXIMAL VENOUS STENT PLACEMENT). ACCORDING TO THE LITERATURE PAPER, 01 PATIENT EXPERIENCED STENT OCCLUSION SYMPTOMS WHICH RESULTED IN AN ENDOVASCULAR TREATMENT AND ADDITIONAL STENT PLACEMENT 22 DAYS POST-PROCEDURE. AS PER MEDICAL ADVISOR INPUT ¿REQUIRE INTERVENTION/ADDITIONAL PROCEDURES TO PREVENT PERMANENT IMPAIRMENT/DAMAGE¿. COMPLAINTS OF THIS NATURE WILL CONTINUE TO BE MONITORED FOR POTENTIAL EMERGING TRENDS.
THE MAIN OBJECTIVE OF THIS AMBISPECTIVE, SINGLE CENTER, NONRANDOMIZED, SINGLE-ARM, PHYSICIAN-DRIVEN STUDY WAS TO EVALUATE THE PATENCY OF THE ZILVER® VENA¿ VENOUS SELF-EXPANDING STENT (I.E., THE ZILVER® VENA¿ VENOUS STENT) IN PATIENTS UNDERGOING VENOUS STENTING. THIS REPORT FOCUSES ON DATA FROM THE 239 PATIENTS THAT HAD A ZILVER VENA VENOUS STENT PLACED AT AN INDEX PROCEDURE. PATIENT 18 HAD RESTENOSIS/RECURRENCE OF SYMPTOMS AND REQUIRED STENT REPLACEMENT. PATIENT 18 HAD A STENT OCCLUSION, WHICH RESULTED IN AN ENDOVASCULAR TREATMENT AND ADDITIONAL STENT PLACEMENT 22 DAYS POST-PROCEDURE AS REPORTED IN TABLE 3.9.1-2. 26 DAYS POST-PROCEDURE NEW THROMBOSIS WAS NOTED PARTIALLY IN THE ILIAC SEGMENT AND ALL OF THE FEMORAL VEIN STENT. THIS WAS REPORTED ALL AS ONE EVENT BY THE PHYSICIAN. RESTENOSIS/RECURRENCE OF THROMBSIS SYMPTOMS: TIME TO DIAGNOSIS 26 DAYS. RELATED TO THE PROCEDURE; RESIDUAL THROMBOSIS AFTER LYSIS OF INFLOW. IMAGING MODALITY TO DIAGNOSE EVENT ULTRSOUND. NO NEW INTERVENTION HAS BEEN PERFORMED TO TREAT THE THROMBUS NOTED 26 DAYS POST-PROCEDURE. PATIENT OUTCOME: REQUIRED IMAGING, ENDOVASCULAR TREATMENT AND STENT REPLACEMENT.
SUPPLEMENTAL REPORT IS BEING SUBMITTED DUE TO THE COMPLETION OF THE INVESTIGATION ON 18-JAN-2023.
Devices
| Seq | Brand | Generic | Product Code | Manufacturer | Model | Lot | UDI-DI |
|---|---|---|---|---|---|---|---|
| 2686825 | ZILVER VENA VENOUS SELF EXPANDING STENT | Stent, iliac vein | QAN | COOK IRELAND LTD | UNKNOWN |
Patients
| Seq | Age | Sex | Outcome | Treatment |
|---|---|---|---|---|
| 1 | Unknown | Required Intervention |